Seeking Priority Review
NPS Files Gattex NDA in SBS; Commercial Plan 'Set in Motion'
By Jennifer Boggs
Friday, December 2, 2011
NPS Pharmaceuticals Inc. completed its new drug application (NDA) submission for Gattex (teduglutide) in short bowel syndrome (SBS), seeking a priority six-month review that could see the orphan drug on the market in the first half of next year.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.